miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression

Purpose: The purpose of this study was to investigate the clinicopathologic significance and potential role of miR-200b and miR-200c in the development and progression of gastric cancer. Experimental Design: We examined miR-200b and miR-200c expression in 36 paired normal and stomach tumor specimens, as well as gastric cancer cell lines, by quantitative real-time PCR. In addition, miR-200b and miR-200c were detected by ISH using gastric cancer tissue microarrays, and the association between miR-200b and miR-200c levels and clinicopathologic factors and prognosis were analyzed. A luciferase assay was conducted for target evaluation. The functional effects of miR-200b and miR-200c on gastric cancer cells were validated by a cell proliferation assay and cell invasion and migration assays. Results: miR-200b and miR-200c were downregulated in the gastric cancer specimens and cell lines tested. miR-200b and miR-200c levels were significantly correlated with the clinical stage, T stage, lymph node metastasis, and survival of patients. Ectopic expression of miR-200b and miR-200c impaired cell growth and invasion. In addition, when overexpressed, miR-200b and miR-200c commonly directly targeted DNMT3A, DNMT3B, and SP1 (a transactivator of the DNMT1 gene), which resulted in marked reduction of the expression of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B at the protein level. This effect, in turn, led to a decrease in global DNA methylation and reexpression of p16, RASS1A1, and E-cadherin via promoter DNA hypomethylation. Conclusion: Our findings suggest that miR-200b and miR-200c, as valuable markers of gastric cancer prognosis, may be a promising approach to human gastric cancer treatment. Clin Cancer Res; 19(20); 5602–12. ©2013 AACR.

[1]  Jun Tang,et al.  Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  F. Slack,et al.  MicroRNA in cancer prognosis. , 2008, The New England journal of medicine.

[3]  Gregory J Goodall,et al.  Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. , 2013, Neoplasia.

[4]  S. Baylin,et al.  Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. , 1999, Cancer research.

[5]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[6]  Shadan Ali,et al.  Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. , 2012, Carcinogenesis.

[7]  J. Willis,et al.  Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer , 2000, Nature Genetics.

[8]  J. Herman,et al.  The fundamental role of epigenetics in hematopoietic malignancies. , 2006, Blood reviews.

[9]  Xiaoping Liu,et al.  LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. , 2012, Current cancer drug targets.

[10]  Kassem M. Makki,et al.  Rnd3/RhoE Is down‐regulated in hepatocellular carcinoma and controls cellular invasion , 2012, Hepatology.

[11]  Hailin Tang,et al.  MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma , 2011, Molecular Cancer.

[12]  J. Black,et al.  Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.

[13]  W. Guo,et al.  Aberrant CpG Island Hypermethylation of RASSF1A in Gastric Cardia Adenocarcinoma , 2009, Cancer investigation.

[14]  Jun Zhan,et al.  Kindlin 2 promotes breast cancer invasion via epigenetic silencing of the microRNA200 gene family , 2013, International journal of cancer.

[15]  S. Kishikawa,et al.  Regulation of transcription of the Dnmt1 gene by Sp1 and Sp3 zinc finger proteins. , 2002, European journal of biochemistry.

[16]  Tao Wang,et al.  Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines. , 2013, Endocrinology.

[17]  Axel Benner,et al.  Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer , 2012, Clinical Cancer Research.

[18]  Y. Bang,et al.  Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy , 2007, Journal of Molecular Medicine.

[19]  C. Bloomfield,et al.  MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. , 2009, Blood.

[20]  Woonyoung Choi,et al.  miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy , 2009, Clinical Cancer Research.

[21]  G. Kang,et al.  Correlation of p16 Hypermethylation with p16 Protein Loss in Sporadic Gastric Carcinomas , 2000, Laboratory Investigation.

[22]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[23]  Hailin Tang,et al.  The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. , 2013, Current cancer drug targets.

[24]  Laisheng Li,et al.  MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1 , 2013, Clinical and Experimental Medicine.

[25]  R. Langer,et al.  DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. , 2011, European journal of cancer.

[26]  Enrica Calura,et al.  Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. , 2011, The Lancet. Oncology.

[27]  André Kajdacsy-Balla,et al.  miR-183-96-182 Cluster Is Overexpressed in Prostate Tissue and Regulates Zinc Homeostasis in Prostate Cells* , 2011, The Journal of Biological Chemistry.

[28]  M. Caligiuri,et al.  Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. , 2008, Blood.

[29]  Xiaoling Li,et al.  miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma , 2011, Journal of Cell Science.

[30]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[31]  Christopher J. Cheng,et al.  The Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer , 2012, Cancer journal.

[32]  B. Aggarwal,et al.  Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. , 2012, Carcinogenesis.

[33]  J. Steen,et al.  Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma , 2012, Acta Neuropathologica.

[34]  B. Xia,et al.  Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China , 2007, BMC Cancer.

[35]  Diane D. Liu,et al.  miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1 , 2010, Molecular Cancer Research.

[36]  Z. Cai,et al.  Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells , 2012, PloS one.

[37]  C. Caldas,et al.  E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma , 2001, Oncogene.